BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27288406)

  • 1. Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells.
    Niu X; He W; Song B; Ou Z; Fan D; Chen Y; Fan Y; Sun X
    J Biol Chem; 2016 Aug; 291(32):16576-85. PubMed ID: 27288406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
    Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
    Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
    Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
    Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
    Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
    Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
    Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
    Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient gene correction of an aberrant splice site in β-thalassaemia iPSCs by CRISPR/Cas9 and single-strand oligodeoxynucleotides.
    Xiong Z; Xie Y; Yang Y; Xue Y; Wang D; Lin S; Chen D; Lu D; He L; Song B; Yang Y; Sun X
    J Cell Mol Med; 2019 Dec; 23(12):8046-8057. PubMed ID: 31631510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells.
    Yingjun X; Yuhuan X; Yuchang C; Dongzhi L; Ding W; Bing S; Yi Y; Dian L; Yanting X; Zeyu X; Nengqing L; Diyu C; Xiaofang S
    Ann Hematol; 2019 Dec; 98(12):2661-2671. PubMed ID: 31495903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Step Biallelic and Scarless Correction of a β-Thalassemia Mutation in Patient-Specific iPSCs without Drug Selection.
    Liu Y; Yang Y; Kang X; Lin B; Yu Q; Song B; Gao G; Chen Y; Sun X; Li X; Bu L; Fan Y
    Mol Ther Nucleic Acids; 2017 Mar; 6():57-67. PubMed ID: 28325300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free β-thalassemia induced pluripotent stem cells.
    Ma N; Liao B; Zhang H; Wang L; Shan Y; Xue Y; Huang K; Chen S; Zhou X; Chen Y; Pei D; Pan G
    J Biol Chem; 2013 Nov; 288(48):34671-9. PubMed ID: 24155235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.
    Xie F; Ye L; Chang JC; Beyer AI; Wang J; Muench MO; Kan YW
    Genome Res; 2014 Sep; 24(9):1526-33. PubMed ID: 25096406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9.
    Wattanapanitch M
    Methods Mol Biol; 2021; 2211():193-211. PubMed ID: 33336279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
    Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
    Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.
    Li L; Yi H; Liu Z; Long P; Pan T; Huang Y; Li Y; Li Q; Ma Y
    Stem Cell Res Ther; 2022 Mar; 13(1):102. PubMed ID: 35255977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 system and its applications in human hematopoietic cells.
    Hu X
    Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in β-Thalassemia Induced Pluripotent Stem Cells (iPSCs).
    Ma N; Shan Y; Liao B; Kong G; Wang C; Huang K; Zhang H; Cai X; Chen S; Pei D; Chen N; Pan G
    J Biol Chem; 2015 May; 290(19):12079-89. PubMed ID: 25795783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
    Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
    Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation.
    Gabr H; El Ghamrawy MK; Almaeen AH; Abdelhafiz AS; Hassan AOS; El Sissy MH
    Stem Cell Res Ther; 2020 Sep; 11(1):390. PubMed ID: 32912325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.